Hyuk-Jeen Suh

Hyuk-Jeen Suh

Director/Board Member at Callidus Biopharma, Inc.

Electronic Technology
Consumer Services
Health Technology

Profile

Hyuk-Jeen Suh is currently a Director at WellDoc, Inc., Callidus Biopharma, Inc., and Maluuba Inc. He is also a General Partner at Skyriver Ventures Management LLC and an Investor Advisor at Yale University.
In the past, he has worked as a Process Engineer at Intel Corp., Senior Research Engineer at Sequenom, Inc., and Senior Manager-Global Marketing at MEMSIC, Inc. He has also served as a Principal at JPMorgan Investment Bank and as a Board Member at NanoPhotonica, Inc. and Adhawk Microsystems, Inc. Dr. Suh holds an MBA from Yale University, an undergraduate and graduate degree from Cornell University, and a doctorate from the University of Illinois.

Hyuk-Jeen Suh active positions

CompaniesPositionStart
Director/Board Member -
Director/Board Member -
Director/Board Member -
Private Equity Investor 2020-09-30
Yale University Consultant / Advisor 2020-03-31
All active positions of Hyuk-Jeen Suh

Former positions of Hyuk-Jeen Suh

CompaniesPositionEnd
Director/Board Member 2019-08-30
Director/Board Member 2019-08-30
Director/Board Member -
Corporate Officer/Principal -
░░░░░ ░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ -
See the detail of Hyuk-Jeen Suh's experience

Training of Hyuk-Jeen Suh

Yale University Masters Business Admin
Cornell University Graduate Degree
University of Illinois Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Hyuk-Jeen Suh's experience

Connections

100 +

1st degree connections

14

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies1
INTEL CORPORATION

Electronic Technology

Private companies10

Health Technology

Technology Services

Commercial Services

Health Technology

Technology Services

Electronic Technology

Commercial Services

Electronic Technology

Finance

Finance

See company connections
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW